EIF2AK4 (eIF-2-alpha kinase GCN2) variants and mutations
EIF2AK4 (also known as eIF-2-alpha kinase GCN2) is a human protein-coding gene encoding an eIF-2-alpha kinase GCN2 protein. It senses amino-acid deprivation and other stresses and reduces global translation through phosphorylation of eIF2alpha. Biallelic loss-of-function variants are a major cause of pulmonary capillary hemangiomatosis and pulmonary veno-occlusive disease. This analysis covers 1,801 EIF2AK4 variants and mutations. Of these, 77% have computational variant effect predictions. Disease context includes Pulmonary capillary hemangiomatosis, pulmonary venoocclusive disease 2, and heritable pulmonary arterial hypertension. Example EIF2AK4 variants include A2V, A2T, and A2S.
Variant analysis overview
- Gene: EIF2AK4
- Protein: eIF-2-alpha kinase GCN2
- UniProt accession: Q9P2K8
- Organism: Homo sapiens
- Variants analyzed: 1801
- Variant scope: all variants
- Completed: 2026-08-21
Variant and mutation evidence
- Variant composition: 1,576 unspecified-consequence records; 131 missense variants; 13 frameshift variants; 64 synonymous variants; 12 stop-gained variants; 1 in-frame insertions; 4 splice-region variants
- Prediction scores: 1,390 variants have prediction scores (77% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Pulmonary capillary hemangiomatosis, pulmonary venoocclusive disease 2, heritable pulmonary arterial hypertension, pulmonary arterial hypertension, pulmonary venoocclusive disease, idiopathic pulmonary arterial hypertension, pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis, pontocerebellar hypoplasia, Non-syndromic pontocerebellar hypoplasia, Umbilical hernia, pulmonary venoocclusive disease 1, hypertensive disorder.
Protein structure and variant hotspots
- Protein features: 3 domains; 2 binding sites; 6 post-translational modification sites.
- Structural context: 903 variants have structural context.
- PTM context: 7 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable EIF2AK4 variants
Examples include A2V, A2T, A2S, A2A, G3R, G3A, G3W, G4A. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2V (p.Ala2Val), Ensembl rs2140892690, REVEL 0.11, MetaLR 0.20
- A2T (p.Ala2Thr), gnomAD 15-39934199-G-A, REVEL 0.10, CADD 23.60
- A2S (p.Ala2Ser), gnomAD 15-39934199-G-T, REVEL 0.12, CADD 22.10
- A2A (p.Ala2Ala), gnomAD 15-39934201-T-C, CADD 14.50
- G3R (p.Gly3Arg), ExAC rs745785010, TOPMed rs745785010, gnomAD rs745785010, REVEL 0.17, MetaLR 0.35
- G3A (p.Gly3Ala), gnomAD 15-39934201-TGGGG, CADD 27.20
- G3W (p.Gly3Trp), gnomAD 15-39934202-G-T, REVEL 0.23, CADD 27.00
- G4A (p.Gly4Ala), rs780175001, ClinGen CA7473358, ClinVar RCV001955336, 1000Genomes rs780175001, REVEL 0.04, MetaLR 0.16, Uncertain significance, not provided
- G4C (p.Gly4Cys), ExAC rs772178376, gnomAD rs772178376
- G4D (p.Gly4Asp), 1000Genomes rs780175001, ExAC rs780175001, TOPMed rs780175001, gnomAD rs780175001, REVEL 0.17, MetaLR 0.18, Uncertain significance
- G4V (p.Gly4Val), 1000Genomes rs780175001, ExAC rs780175001, TOPMed rs780175001, gnomAD rs780175001, REVEL 0.16, MetaLR 0.22, Uncertain significance
- G4R (p.Gly4Arg), gnomAD 15-39934205-G-C, REVEL 0.10, CADD 23.10
- G4G (p.Gly4Gly), gnomAD 15-39934207-C-A, CADD 11.80
- R5C (p.Arg5Cys), 1000Genomes rs746773845, ExAC rs746773845, TOPMed rs746773845, gnomAD rs746773845, REVEL 0.32, MetaLR 0.19
- R5G (p.Arg5Gly), 1000Genomes rs746773845, ExAC rs746773845, TOPMed rs746773845, gnomAD rs746773845, REVEL 0.18, MetaLR 0.18
- R5P (p.Arg5Pro), TOPMed rs1345360796, gnomAD rs1345360796, REVEL 0.37, MetaLR 0.18
- R5S (p.Arg5Ser), gnomAD 15-39934208-C-A, REVEL 0.12, CADD 19.60
- R5L (p.Arg5Leu), gnomAD 15-39934209-G-T, REVEL 0.27, CADD 22.30
- R5H (p.Arg5His), gnomAD 15-39934209-G-A, REVEL 0.13, CADD 22.50
- G6A (p.Gly6Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G6R (p.Gly6Arg), NCI-TCGA TCGA novel, REVEL 0.10, MetaLR 0.17, Variant assessed as somatic; moderate impact.
- G6W (p.Gly6Trp), gnomAD 15-39934211-G-T, REVEL 0.26, CADD 24.00
- G6E (p.Gly6Glu), gnomAD 15-39934212-G-A, REVEL 0.10, CADD 18.20
- G6G (p.Gly6Gly), rs1334881640, gnomAD 15-39934213-G-C, CADD 5.79
- A7P (p.Ala7Pro), ExAC rs776846678, TOPMed rs776846678, gnomAD rs776846678, REVEL 0.20, MetaLR 0.15
- A7S (p.Ala7Ser), ExAC rs776846678, TOPMed rs776846678, gnomAD rs776846678, REVEL 0.04, MetaLR 0.13
- A7T (p.Ala7Thr), ExAC rs776846678, TOPMed rs776846678, gnomAD rs776846678, REVEL 0.04, MetaLR 0.14, Uncertain significance, Inborn genetic diseases
- A7V (p.Ala7Val), cosmic curated COSV55464, TOPMed rs913851324, gnomAD rs913851324, REVEL 0.03, MetaLR 0.15
- A7D (p.Ala7Asp), gnomAD 15-39934215-C-A, REVEL 0.05, CADD 8.12
- A7G (p.Ala7Gly), gnomAD 15-39934215-C-G, REVEL 0.03, CADD 5.45
- A7A (p.Ala7Ala), gnomAD 15-39934216-C-T, CADD 6.89
- P8H (p.Pro8His), gnomAD rs2034028168, REVEL 0.13, MetaLR 0.14
- P8L (p.Pro8Leu), gnomAD rs2034028168, REVEL 0.07, MetaLR 0.14
- P8S (p.Pro8Ser), TOPMed rs1315471968, gnomAD rs1315471968, REVEL 0.08, MetaLR 0.10
- P8R (p.Pro8Arg), rs2034028227, gnomAD 15-39934217-CCCGG, CADD 29.80
- P8T (p.Pro8Thr), gnomAD 15-39934217-C-A, REVEL 0.07, CADD 5.51
- P8P (p.Pro8Pro), rs769852698, gnomAD 15-39934219-C-T, CADD 9.20
- G9E (p.Gly9Glu), ExAC rs773331885, gnomAD rs773331885, REVEL 0.07, MetaLR 0.17
- G9V (p.Gly9Val), ExAC rs773331885, gnomAD rs773331885, REVEL 0.12, MetaLR 0.20
- G9R (p.Gly9Arg), gnomAD 15-39934214-G-GC, CADD 21.50
- G9W (p.Gly9Trp), gnomAD 15-39934220-G-T, REVEL 0.20, CADD 24.70
- R10G (p.Arg10Gly), gnomAD rs2034028377
- R10P (p.Arg10Pro), TOPMed rs2034028417, gnomAD rs2034028417, REVEL 0.26, MetaLR 0.16
- R10A (p.Arg10Ala), rs1284752783, gnomAD 15-39934214-GC-G, CADD 14.40
- R10S (p.Arg10Ser), gnomAD 15-39934223-C-A, REVEL 0.12, CADD 17.80
- R10C (p.Arg10Cys), gnomAD 15-39934223-C-T, REVEL 0.19, CADD 23.30
- R10H (p.Arg10His), gnomAD 15-39934224-G-A, REVEL 0.09, CADD 22.70
- R10R (p.Arg10Arg), gnomAD 15-39934225-C-A, CADD 10.60
- G11R (p.Gly11Arg), ExAC rs766830247, TOPMed rs766830247, gnomAD rs766830247, REVEL 0.30, MetaLR 0.19
- G11S (p.Gly11Ser), ExAC rs766830247, TOPMed rs766830247, gnomAD rs766830247, REVEL 0.17, MetaLR 0.18
- G11C (p.Gly11Cys), gnomAD 15-39934226-G-T, REVEL 0.29, CADD 24.50
- G11V (p.Gly11Val), gnomAD 15-39934227-G-T, REVEL 0.20, CADD 22.70
- G11D (p.Gly11Asp), gnomAD 15-39934227-G-A, REVEL 0.19, CADD 23.70
- G11A (p.Gly11Ala), gnomAD 15-39934227-G-C, REVEL 0.16, CADD 21.40
- G11G (p.Gly11Gly), rs1366522831, gnomAD 15-39934228-C-A, CADD 10.10
- R12Q (p.Arg12Gln), gnomAD rs1166947460, REVEL 0.06, MetaLR 0.11
- R12W (p.Arg12Trp), gnomAD 15-39934229-C-T, REVEL 0.12, CADD 23.30
- R12G (p.Arg12Gly), gnomAD 15-39934229-C-G, REVEL 0.07, CADD 21.20
- R12R (p.Arg12Arg), gnomAD 15-39934229-C-A, CADD 14.70
- R12P (p.Arg12Pro), gnomAD 15-39934230-G-C, REVEL 0.09, CADD 22.30
- D13E (p.Asp13Glu), TOPMed rs902159029, REVEL 0.07, MetaLR 0.07
- D13N (p.Asp13Asn), TOPMed rs1418526168, gnomAD rs1418526168
- D13Y (p.Asp13Tyr), TOPMed rs1418526168, gnomAD rs1418526168, REVEL 0.12, MetaLR 0.13
- D13G (p.Asp13Gly), gnomAD 15-39934233-A-G, REVEL 0.05, CADD 22.30
- E14A (p.Glu14Ala), rs2504511999, ClinGen CA391686009, ClinVar RCV002732040, Uncertain significance, Inborn genetic diseases
- E14Q (p.Glu14Gln), ExAC rs774742348, gnomAD rs774742348, REVEL 0.09, MetaLR 0.18
- E14* (p.Glu14Ter), gnomAD 15-39934235-G-T, CADD 39.00
- E14E (p.Glu14Glu), rs999615332, gnomAD 15-39934237-G-A, CADD 12.50
- E14D (p.Glu14Asp), gnomAD 15-39934237-G-T, REVEL 0.05, CADD 17.60
- P15L (p.Pro15Leu), ExAC rs759887590, TOPMed rs759887590, gnomAD rs759887590, REVEL 0.13, MetaLR 0.14
- P15S (p.Pro15Ser), gnomAD 15-39934238-C-T, REVEL 0.06, CADD 20.20
- P15T (p.Pro15Thr), gnomAD 15-39934238-C-A, REVEL 0.03, CADD 19.80
- P15P (p.Pro15Pro), rs1356420976, gnomAD 15-39934240-T-G, CADD 9.55
- P16A (p.Pro16Ala), gnomAD rs1443167446, REVEL 0.08, MetaLR 0.10
- P16L (p.Pro16Leu), rs922734815, ClinGen CA268745496, ClinVar RCV004377721, TOPMed rs922734815, REVEL 0.09, MetaLR 0.13, Uncertain significance, Inborn genetic diseases
- P16R (p.Pro16Arg), TOPMed rs922734815, gnomAD rs922734815, REVEL 0.08, MetaLR 0.14, Uncertain significance
- P16T (p.Pro16Thr), gnomAD 15-39934241-C-A, REVEL 0.06, CADD 16.40
- P16P (p.Pro16Pro), rs369817117, gnomAD 15-39934243-G-A, CADD 11.20
- E17* (p.Glu17Ter), gnomAD 15-39934244-G-T, CADD 40.00
- E17Q (p.Glu17Gln), gnomAD 15-39934244-G-C, REVEL 0.18, CADD 25.20
- E17D (p.Glu17Asp), gnomAD 15-39934246-G-T, REVEL 0.06, CADD 22.20
- S18I (p.Ser18Ile), gnomAD rs1489318389, REVEL 0.16, MetaLR 0.21
- S18S (p.Ser18Ser), gnomAD 15-39934249-C-T, CADD 16.50
- S18R (p.Ser18Arg), gnomAD 15-39934249-C-G, REVEL 0.19, CADD 27.70
- Y19C (p.Tyr19Cys), NCI-TCGA Cosmic COSV5546, cosmic curated COSV55465, Variant assessed as somatic; moderate impact.
- Y19H (p.Tyr19His), gnomAD 15-39934250-T-C, REVEL 0.19, CADD 26.10
- P20R (p.Pro20Arg), ExAC rs753520346, TOPMed rs753520346, gnomAD rs753520346, REVEL 0.03, MetaLR 0.03, Uncertain significance, not provided
- P20T (p.Pro20Thr), TOPMed rs2034029108, gnomAD rs2034029108, REVEL 0.02, MetaLR 0.04
- P20S (p.Pro20Ser), gnomAD 15-39934253-C-T, REVEL 0.03, CADD 18.90
- P20Q (p.Pro20Gln), gnomAD 15-39934254-C-A, REVEL 0.03, CADD 18.90
- P20P (p.Pro20Pro), rs372761392, gnomAD 15-39934255-G-A, CADD 15.00
- Q21* (p.Gln21Ter), gnomAD rs1355402531, CADD 39.00
- Q21K (p.Gln21Lys), gnomAD rs1355402531, REVEL 0.13, MetaLR 0.12
- Q21N (p.Gln21Asn), rs2034029277, gnomAD 15-39934254-CG-C, CADD 25.30
- R22L (p.Arg22Leu), TOPMed rs2034029457, REVEL 0.15, MetaLR 0.10
- R22* (p.Arg22Ter), gnomAD 15-39934259-C-T, CADD 37.00
- R22R (p.Arg22Arg), rs2034029417, gnomAD 15-39934259-C-A, CADD 15.80
- R22Q (p.Arg22Gln), gnomAD 15-39934260-G-A, REVEL 0.13, CADD 24.20
- Q23* (p.Gln23Ter), ExAC rs749915180, TOPMed rs749915180, gnomAD rs749915180, CADD 39.00
- Q23E (p.Gln23Glu), ExAC rs749915180, TOPMed rs749915180, gnomAD rs749915180, REVEL 0.41, MetaLR 0.40
- Q23H (p.Gln23His), ExAC rs758007786, REVEL 0.54, MetaLR 0.30
- Q23R (p.Gln23Arg), gnomAD 15-39934263-A-G, REVEL 0.45, CADD 27.00
- Q23Q (p.Gln23Gln), rs758007786, gnomAD 15-39934264-G-A, CADD 14.10
- D24E (p.Asp24Glu), Ensembl rs2140892773
- D24N (p.Asp24Asn), gnomAD rs1308786743, REVEL 0.10, MetaLR 0.07
- D24Y (p.Asp24Tyr), gnomAD 15-39934265-G-T, REVEL 0.21, CADD 32.00
- D24G (p.Asp24Gly), gnomAD 15-39934266-A-G, REVEL 0.12, CADD 25.60
- H25Q (p.His25Gln), ESP rs374991853, ExAC rs374991853, TOPMed rs374991853, gnomAD rs374991853, REVEL 0.17, MetaLR 0.07, Likely benign
- H25H (p.His25His), rs374991853, gnomAD 15-39934270-C-T, CADD 14.50
- E26* (p.Glu26Ter), NCI-TCGA Cosmic COSV5547, cosmic curated COSV55475, CADD 41.00, Variant assessed as somatic; high impact.
- E26K (p.Glu26Lys), gnomAD 15-39934271-G-A, REVEL 0.86, CADD 32.00
- E26E (p.Glu26Glu), gnomAD 15-39934273-G-A, CADD 14.30
- L27I (p.Leu27Ile), gnomAD 15-39934274-C-A, REVEL 0.19, CADD 24.90
- L27V (p.Leu27Val), gnomAD 15-39934274-C-G, REVEL 0.22, CADD 32.00
- L27P (p.Leu27Pro), gnomAD 15-39934275-T-C, REVEL 0.66, CADD 32.00
- L27L (p.Leu27Leu), rs1490181896, gnomAD 15-39934276-A-G, CADD 15.60
- Q28* (p.Gln28Ter), rs2034029835, ClinGen CA391686362, ClinVar RCV001289847, Ensembl rs2034029835, Likely pathogenic
- Q28P (p.Gln28Pro), gnomAD 15-39934278-A-C, REVEL 0.26, CADD 27.50
- Q28R (p.Gln28Arg), gnomAD 15-39934278-A-G, REVEL 0.14, CADD 26.10
- Q28Q (p.Gln28Gln), rs746925938, gnomAD 15-39934279-G-A, CADD 14.70
- A29S (p.Ala29Ser), gnomAD 15-39934280-G-T, REVEL 0.17, CADD 26.00
- A29D (p.Ala29Asp), gnomAD 15-39934281-C-A, REVEL 0.42, CADD 27.10
- A29A (p.Ala29Ala), rs553269049, gnomAD 15-39934282-C-T, CADD 10.30
- L30P (p.Leu30Pro), gnomAD 15-39934284-T-C, REVEL 0.69, CADD 32.00
- L30L (p.Leu30Leu), gnomAD 15-39934285-G-T, CADD 14.70
- E31D (p.Glu31Asp), NCI-TCGA TCGA novel, REVEL 0.11, MetaLR 0.09, Variant assessed as somatic; moderate impact.
- E31* (p.Glu31Ter), gnomAD 15-39934286-G-T, CADD 42.00
- E31Q (p.Glu31Gln), gnomAD 15-39934286-G-C, REVEL 0.11, CADD 25.20
- A32V (p.Ala32Val), gnomAD 15-39934290-C-T, REVEL 0.20, CADD 25.20
- A32A (p.Ala32Ala), rs780909041, gnomAD 15-39934291-C-T, CADD 16.00
- I33N (p.Ile33Asn), gnomAD 15-39934293-T-A, REVEL 0.58, CADD 32.00
- I33I (p.Ile33Ile), rs566792, gnomAD 15-39934294-T-C, CADD 15.80
- p.Ile33 Tyr34insThrAlaArgThrSerL, gnomAD 15-39934294-T-TAC, CADD 21.50
- Y34C (p.Tyr34Cys), gnomAD 15-39934296-A-G, REVEL 0.63, CADD 32.00
- Y34* (p.Tyr34Ter), gnomAD 15-39934297-C-A, CADD 36.00
- Y34Y (p.Tyr34Tyr), rs770042053, gnomAD 15-39934297-C-T, CADD 13.90
- G35D (p.Gly35Asp), cosmic curated COSV99775, Ensembl rs1208550068, REVEL 0.17, MetaLR 0.09
- G35C (p.Gly35Cys), gnomAD 15-39934298-G-T, REVEL 0.34, CADD 27.20
- G35V (p.Gly35Val), gnomAD 15-39934299-G-T, REVEL 0.20, CADD 29.00
- G35G (p.Gly35Gly), gnomAD 15-39934300-C-A, CADD 13.90
- A36E (p.Ala36Glu), ExAC rs773452712, gnomAD rs773452712
- A36S (p.Ala36Ser), rs1417044761, ClinGen CA391686554, ClinVar RCV002902514, NCI-TCGA TCGA novel, REVEL 0.02, MetaLR 0.03, Uncertain significance, Inborn genetic diseases
- A36T (p.Ala36Thr), gnomAD rs1417044761, REVEL 0.01, MetaLR 0.03, Uncertain significance, Inborn genetic diseases
- A36V (p.Ala36Val), ExAC rs773452712, gnomAD rs773452712, REVEL 0.02, MetaLR 0.06
- A36A (p.Ala36Ala), gnomAD 15-39934303-G-T, CADD 11.80
- D37E (p.Asp37Glu), TOPMed rs1311239157
- D37Y (p.Asp37Tyr), gnomAD 15-39934304-G-T, REVEL 0.51, CADD 32.00
- D37N (p.Asp37Asn), gnomAD 15-39934304-G-A, REVEL 0.29, CADD 29.30
- D37D (p.Asp37Asp), gnomAD 15-39934306-C-T, CADD 14.90
- F38I (p.Phe38Ile), gnomAD 15-39934307-T-A, REVEL 0.23, CADD 23.70
- F38L (p.Phe38Leu), gnomAD 15-39934307-T-C, REVEL 0.17, CADD 22.40
- Q39E (p.Gln39Glu), rs771007706, ClinGen CA7473383, ClinVar RCV004377705, ExAC rs771007706, REVEL 0.14, MetaLR 0.04, Uncertain significance, Inborn genetic diseases
- Q39Q (p.Gln39Gln), rs774854435, gnomAD 15-39934312-A-G, CADD 12.60
- D40E (p.Asp40Glu), TOPMed rs2034030555, REVEL 0.19, MetaLR 0.16
- D40Y (p.Asp40Tyr), gnomAD 15-39934313-G-T, REVEL 0.50, CADD 30.00
- D40D (p.Asp40Asp), gnomAD 15-39934315-C-T, CADD 12.40
- L41M (p.Leu41Met), gnomAD 15-39934316-C-A, REVEL 0.20, CADD 25.30
- L41P (p.Leu41Pro), gnomAD 15-39934317-T-C, REVEL 0.48, CADD 31.00
- L41R (p.Leu41Arg), gnomAD 15-39934317-T-G, REVEL 0.40, CADD 29.10
- R42P (p.Arg42Pro), ESP rs372615103, ExAC rs372615103, TOPMed rs372615103, gnomAD rs372615103, Uncertain significance
- R42Q (p.Arg42Gln), rs372615103, ClinGen CA7473385, ClinVar RCV002748853, ESP rs372615103, REVEL 0.13, MetaLR 0.24, Uncertain significance, Inborn genetic diseases
- R42W (p.Arg42Trp), gnomAD 15-39934319-C-T, REVEL 0.37, CADD 29.00
- R42R (p.Arg42Arg), gnomAD 15-39934319-C-A, CADD 14.60
- R42L (p.Arg42Leu), gnomAD 15-39934320-G-T, REVEL 0.23, CADD 29.70
- P43L (p.Pro43Leu), Ensembl rs2034030721, REVEL 0.10, MetaLR 0.08
- P43S (p.Pro43Ser), gnomAD 15-39934322-C-T, REVEL 0.03, CADD 17.00
- P43T (p.Pro43Thr), gnomAD 15-39934322-C-A, REVEL 0.03, CADD 16.90
- P43P (p.Pro43Pro), rs775764964, gnomAD 15-39934324-G-T, CADD 9.53
- D44E (p.Asp44Glu), ExAC rs761154197, TOPMed rs761154197, gnomAD rs761154197, REVEL 0.03, MetaLR 0.05
- D44H (p.Asp44His), TOPMed rs1355293664, gnomAD rs1355293664, REVEL 0.06, MetaLR 0.07
- D44N (p.Asp44Asn), TOPMed rs1355293664, gnomAD rs1355293664, REVEL 0.01, MetaLR 0.04
- D44Y (p.Asp44Tyr), TOPMed rs1355293664, gnomAD rs1355293664, REVEL 0.16, MetaLR 0.08
- D44D (p.Asp44Asp), rs761154197, gnomAD 15-39934327-C-T, CADD 8.99
- A45P (p.Ala45Pro), gnomAD 15-39934328-G-C, REVEL 0.11, CADD 19.10
- A45S (p.Ala45Ser), gnomAD 15-39934328-G-T, REVEL 0.08, CADD 14.50
- C46R (p.Cys46Arg), gnomAD rs1272475955, REVEL 0.01, MetaLR 0.01
- C46Y (p.Cys46Tyr), ExAC rs764935060, gnomAD rs764935060, REVEL 0.02, MetaLR 0.02
- C46G (p.Cys46Gly), gnomAD 15-39934331-T-G, REVEL 0.01, CADD 7.98
- C46F (p.Cys46Phe), gnomAD 15-39934332-G-T, REVEL 0.02, CADD 14.20
- C46C (p.Cys46Cys), rs2034031072, gnomAD 15-39934333-C-T, CADD 11.90
Public EIF2AK4 analysis runs
- EIF2AK4 analysis run — EIF2AK4 (1,801 variants) — completed 2026-08-21